21 results about "Memory B cell" patented technology

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The invention relates to the field of antibody engineering, in particular to a monoclonal antibody specifically targeting a monkey pox virus and application of the monoclonal antibody. According to the invention, by screening mouse memory B cells specifically combined with monkey pox virus envelope protein A35R, monkey pox virus antibodies 1H4, 3H3, 3H6, 13H1 and 17H1 with high neutralization activity are obtained. Wherein 17H1 has excellent affinity and neutralizing efficacy on monkey pox virus and has a strong in-vivo protection effect, and 100% of survival rate of challenged mice is achieved in prevention and treatment experiments. The sequence of the antibody is completely different from that of an existing monkey pox virus antibody, and a new candidate product is provided for detection, diagnosis, prevention and treatment of the monkey pox virus.

The invention discloses a novel benzothiazole compound as well as a preparation method and application thereof. According to the novel benzothiazole compound, through targeted activation of an RIG-I / OAS innate immune pathway, expression of key proteins and genes such as OAS1 and RIG-I can be rapidly up-regulated, secretion of type I interferon and proinflammatory factors is induced, and instant immune enhancement is achieved; more importantly, by performing long-term functional reprogramming on innate immune cells (such as mononuclear cells and dendritic cells), persistent'innate immune memory '(namely immune domestication) can be induced. The dual-action mechanism can significantly enhance the activation of antigen presenting cells and promote the generation and long-term maintenance of memory B cells and effector memory T cells, has no significant toxicity to liver functions, can be used as an immunologic adjuvant and an immunodomestication molecule of an RSV vaccine, can synergistically improve the vaccine-induced RSV specific antibody titer and neutralizing antibody level, and can be used for preparing an immunologic adjuvant for the RSV vaccine. Long-acting immune protection is provided, and a brand new solution is provided for research and development of RSV vaccines.

Provided herein are vaccine compositions for use in the stimulation of broad-spectrum memory B cell expansion in a patient that has been exposed or is at risk of exposure to an infectious agent of unknown etiology. The composition comprises IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family. Further contemplated herein are compositions and methods of stimulating germinal B cell expansion in a patient, the composition comprising IL-15 or an IL-15 analog and a nucleic acid, wherein the nucleic acid encodes at least one immunogenic peptide, and wherein the composition is administered either subcutaneously or directly into a lymph node.

This invention relates to the field of immunology, specifically to a method for inducing the formation of memory B cells in vitro and its uses, and particularly to the in vitro screening of drugs that promote or inhibit the formation of memory B cells based on the method.

This application relates to humanized monoclonal antibodies against monkeypox virus and their applications. By screening humanized mouse anti-B6R specific binding memory B cells with fully human antibodies, humanized high-neutralizing activity monkeypox virus antibodies B6R-16A1, B6R-21G7, B6R-22D12, B6R-22F9, and B6R-22H1 were obtained. These antibodies have the characteristics of strong binding ability to monkeypox virus, good in vitro neutralization, high affinity, and in vivo protective effect.

The present application relates to monkeypox virus human monoclonal antibody and its application, through screening human antibody humanization mouse anti A29L specific binding memory B cell, the human source high neutralization activity monkeypox virus antibody A29L-1B3, A29L-1B2, A29L-1A5 and A29L-1A2 obtained, have the characteristics such as strong monkeypox virus binding ability, good in-vitro neutralization, affinity, have in-vivo protective effect, and are completely different from the monkeypox virus antibody sequence reported, provide the product for the detection and neutralization of monkeypox virus, and provide the possibility for providing the monkeypox virus product with in-vivo protective effect.

The invention relates to the technical field of biological medicines, in particular to an anti-human helicobacter pylori fully-humanized monoclonal antibody as well as a preparation method and application thereof. The monoclonal antibody comprises one or more of a 4H1-A + 4 lambda 1-25 antibody, a 4H1-A + 4 lambda 1-6 antibody and a 4H1-A + 4 lambda 1-21 antibody; wherein the 4H1-A + 4 lambda 1-25 antibody comprises a 4H1-A heavy chain variable region and a 4 lambda 1-25 light chain variable region; the 4H1-A + 4 lambda 1-6 antibody comprises a 4H1-A heavy chain variable region and a 4 lambda 1-6 light chain variable region; the 4H1-A + 4 lambda 1-21 antibody comprises a 4H1-A heavy chain variable region and a 4 lambda 1-21 light chain variable region. According to the invention, the high-affinity human helicobacter pylori infection-resistant full-human monoclonal antibody is screened through a specific screening method after in-vitro activation of human memory B cells in a laboratory, and an important basis is provided for detection, neutralization and treatment of human helicobacter pylori.

Compositions and methods are provided for determining the presence of early-stage osteoarthritis (OA) in an individual by single cell profiling of B cell population(s) in a blood sample. Expansion of CD25hi switched memory B cells is detectable in the early stages of OA and can be utilized for early detection of the disease.

Provided are a group of fully human thyrotropin receptor (TSHR) (TSH receptor, TSHR) blocking monoclonal antibodies belonging to a SH1 homocluster, a preparation method therefor, and a use thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and individual memory B cells, which specifically recognize TSHR, from peripheral blood of a patient having a high TSH receptor blocking antibody (TBAb) titer, cloning antibody light and heavy chains in vitro, followed by recombinant expression, and performing antibody characteristic screening and verification by using hTSHR-CHO cells, thereby obtaining blocking monoclonal antibodies that specifically target human TSHR. The fully human TSH receptor blocking monoclonal antibodies can specifically bind to TSHR, thereby enabling effective blockage of signal transduction after TSH binds to the receptor, inhibiting the synthesis and secretion of thyroid hormones, and significantly reducing and suppressing the expression of TSHR and fibrosis in orbital fibroblasts, the effector cells in thyroid-related eye diseases. The present invention has broad application prospects in the treatment of Graves' diseases and diseases caused by hyperthyroidism, such as thyroid eye diseases.

The present application relates to monkeypox virus human monoclonal antibody and its application, through screening human antibody humanization mouse anti E8L specific binding memory B cell, the human source high neutralization activity monkeypox virus antibody E8L-7H4, E8L-7H2, E8L-7E7, E8L-8D6 and E8L-7C9 obtained, with the characteristics of strong monkeypox virus binding capacity, good in vitro neutralization, affinity, with in vivo protection, completely different from the reported monkeypox virus antibody sequence, provide the product for the detection and neutralization of monkeypox virus, provide the possibility for the monkeypox virus product with in vivo protection.

The invention relates to the field of breast cancer treatment, in particular to a PDIA3 protein targeting monoclonal antibody and application of the PDIA3 protein targeting monoclonal antibody in breast cancer treatment. According to the present invention, the IgG antibody in tumors, lymph nodes and serum is detected by using the IP-MS technology, the breast cancer tumor antigen disulfide isomerase A3 (PDIA3) is screened by analyzing the characteristics of the IgG antibody, and it is proved that the PDIA3 antigen can induce the breast cancer mouse model to produce the local humoral immune response. Meanwhile, it is found that a PDIA3 specific monoclonal antibody based on memory B cell reconstruction in TLN shows potent immune effect activity, wherein an Ab88 antibody can mediate an ADCC / ADCP effect and inhibit tumor growth. In conclusion, the invention provides the local targeting antigen PDIA3 protein with antibody therapy transformation potential and the specific antibody Ab88 thereof, and a new choice is provided for accurate treatment of breast cancer.

This application discloses a human monoclonal antibody against Hennipa virus and its preparation and application as a bispecific antibody. By screening memory B cells in fully human antibody-transgenic mice that specifically bind to Nipah virus glycoproteins (G and F proteins), human monoclonal antibodies 14B8 (targeting the F protein) and 4B8 (targeting the G protein) were obtained. Simultaneously, a bispecific antibody 14B8-IgG-4B8-scFv was constructed based on the above antibodies, which is formed by fusing the full antibody (IgG) of 14B8 with a single-chain antibody fragment of 4B8. Experiments demonstrated that the above antibodies exhibit extremely high binding affinity and neutralizing activity against NiV and HeV, and provide excellent in vivo protective efficacy in the LVG Golden Hamster model.

The present invention relates to a method for memory B cell-specific differentiation induction and to uses thereof and, more specifically, to an anti-CD3 antibody or ligand in a biological sample obtained from and individual, a method for memory B cell-specific differentiation induction comprising a step of treating an anti-CD28 antibody or ligand, and a method for detection a memory B cell which is specific to a specific antigen by using same.

This invention relates to the field of biotechnology and provides a method for screening positive single B cells that secrete target substances and a method for preparing monoclonal antibodies. The positive single B cell screening method includes the following steps: isolating PBMCs from the peripheral blood of immunized animals; sorting memory B cells using magnetic beads and separation antibodies; activating and culturing memory B cells in vitro using an activation medium; and loading, analyzing, and exporting target positive cells from the activated memory B cells using a Beacon single-cell photoconductive system. This invention achieves high-throughput screening of FYL positive single B cells through the Beacon single-cell photoconductive system. Gene products are obtained through reverse transcription and PCR amplification, and accurate sequences are obtained through sequence analysis. The synthesized plasmid is expressed in a eukaryotic system, and high-purity FYL rabbit monoclonal antibodies are obtained through affinity chromatography, laying the foundation for the development of a rapid fentanyl detection kit.

The present invention relates to the technical field of biology, and provides a method for enabling a plasma cell to capture an antibody secreted by the plasma cell. Specifically, the method comprises: labeling the plasma cell with a capture reagent; and performing single-cell encapsulation treatment on the labeled plasma cell to capture an antibody, wherein the capture reagent has the activity of binding the antibody secreted by the plasma cell, and the plasma cell has the activity of secreting the antibody. By means of the method, the antibody secreted by the plasma cell can be recaptured onto the membrane surface of the plasma cell to form a structure similar to a BCR of a memory B cell, enabling a corresponding antigen protein to specifically recognize and bind to the BCR on the membrane surface of the plasma cell, thereby enabling screening and sequencing of an antigen-specific plasma cell.

This application discloses a monoclonal antibody against monkeypox virus A35R protein or its antigen-binding fragment and its application. A monkeypox virus antibody A35R-10G7 with high protective efficacy was obtained by screening humanized mouse memory B cells that specifically bind to A35R using fully human antibodies. This antibody exhibits strong binding ability to monkeypox virus, high affinity, and in vivo protective activity.

The present invention relates to a method, in particular an in vitro method, for identifying memory B cells, comprising analyzing epigenetic modifications / properties of (including the methylation status) of at least one CpG position in the mammalian gene region for Chromobox protein homolog 6 (CBX6), wherein a demethylation or lack of methylation of said gene region is indicative for a memory B cell, when compared to a non-memory B cell. The analyses according to the invention can identify memory B cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The resent invention furthermore provides an improved method for quantifying memory B cells, in particular in complex samples. The method can be performed without a step of purifying and / or enriching cells, preferably in whole blood and / or non-trypsinized tissue.

The invention discloses application of Macranthoidin B in a vaccine adjuvant, relates to application of Macranthoidin B, and belongs to the technical field of biological medicines. The invention mainly aims at providing a brand new application of the Macranthoidin B, namely the application of the Macranthoidin B in preparation of a vaccine adjuvant. The invention provides an application of Macranthoidin B in preparation of a vaccine adjuvant. The Macranthoidin B is used as an active component of a vaccine adjuvant in the vaccine composition. When the Macranthoidin B is combined with a protein antigen (ovalbumin) for use, the Macranthoidin B can induce to generate adaptive immune responses which are obviously better than reference adjuvants QS-21 and R848, and the adaptive immune responses comprise higher-level antigen-specific IgG, more antigen-specific memory B cells and stronger antigen-specific T cell reactions. Meanwhile, the Macranthoidin B does not cause obvious hepatotoxicity in an effective dose, and has better safety. The invention provides a new candidate compound for developing an efficient and safe vaccine adjuvant.

The application provides a biomarker combination for in vitro diagnosis of membranous nephropathy, comprising non-classical monocytes, CD4+ T cells, effector CD4+ T cells, type 2 helper T cells, double negative T cells, central memory CD4+ T cells, plasmacytoid dendritic cells, antibody-secreting cells, total T cells, unswitched memory B cells, classical monocytes and natural killer cells. The application also provides a method for constructing a membranous nephropathy diagnosis model, comprising a step of screening characteristic biomarkers and a step of constructing and evaluating the performance of a diagnosis model. The application screens the optimal marker combination from high-dimensional flow cytometry data by applying a random forest recursive feature elimination algorithm, and constructs a random forest diagnosis model. The application shows excellent performance in distinguishing membranous nephropathy patients from healthy controls, and demonstrates high accuracy in independent verification including a difficult-to-diagnose subgroup of PLA2R antibody-negative patients.